Results 41 to 50 of about 58,682 (199)

Effect of green tea catechins on the pharmacokinetics of digoxin in humans

Drug Design, Development and Therapy, 2018
Background Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1. This study aimed to investigate the effect of green tea on the pharmacokinetics of digoxin, a typical probe drug of p-gp ...
Tae-Eun Kim, K. Shin, Jeong-Eun Park, Min-Gul Kim, Y. Yun, D. Choi, K. Kwon, Jongmin Lee   +7 more
semanticscholar   +1 more source

Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta [PDF]

, 2013
Despite numerous examples of the effects of the human gastrointestinal microbiome on drug efficacy and toxicity, there is often an incomplete understanding of the underlying mechanisms. Here, we dissect the inactivation of the cardiac drug digoxin by the
Balskus, Emily Patricia, Chatman, Kelly, Gootenberg, David Benjamin, Haiser, Henry J., Sirasani, Gopal, Turnbaugh, Peter   +5 more
core   +1 more source

Management of digoxin toxicity.

Australian Prescriber, 2016
Digoxin toxicity can emerge during long-term therapy as well as after an overdose. It can occur even when the serum digoxin concentration is within the therapeutic range. Toxicity causes anorexia, nausea, vomiting and neurological symptoms.
M. Pincus
semanticscholar   +1 more source

Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain [PDF]

, 2017
There is accumulating evidence that bumetanide, which has been used over decades as a potent loop diuretic, also exerts effects on brain disorders, including autism, neonatal seizures, and epilepsy, which are not related to its effects on the kidney but ...
Erker, Thomas, Fedrowitz, Maren, Hampel, Philip, Kaczmarek, Edith, Löscher, Wolfgang, Römermann, Kerstin, Sweet, Douglas H., Töllner, Kathrin   +7 more
core   +2 more sources

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations

Journal of Pharmacology and Experimental Therapeutics, 2017
Development of submodels of organs within physiologically-based pharmacokinetic (PBPK) principles and beyond simple perfusion limitations may be challenging because of underdeveloped in vitro-in vivo extrapolation approaches or lack of suitable clinical ...
Daniel Scotcher, Christopher R. Jones, A. Galetin, A. Rostami-Hodjegan   +3 more
semanticscholar   +1 more source

Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure

European Heart Journal, 2017
Despite development of new and innovative medical therapies, still millions of patients with chronic heart failure (HF) with reduced ejection fraction and/or atrial fibrillation (AF) are treated with cardiac glycosides (overall 122 millions of patients ...
U. Bavendiek, L. Aguirre Dávila, A. Koch, J. Bauersachs   +3 more
semanticscholar   +1 more source

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

Clinical pharmacology and therapy, 2016
This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P‐gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2‐K), and 10 mg ...
P. Stopfer, T. Giessmann, K. Hohl, Ashish Sharma, N. Ishiguro, M. Taub, H. Zimdahl‐Gelling, D. Gansser, M. Wein, T. Ebner, F. Müller   +10 more
semanticscholar   +1 more source

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2017
Background Digoxin is widely used in patients with atrial fibrillation despite the lack of randomized controlled trials. Observational studies report conflicting results regarding its association with mortality, perhaps because of residual confounding by
A. Eisen, C. Ruff, E. Braunwald, Rose A. Hamershock, B. Lewis, C. Hassager, T. Chao, J. Le Heuzey, M. Mercuri, H. Rutman, E. Antman, R. Giugliano   +11 more
semanticscholar   +1 more source

Digoxin Use Is Associated With Reduced Interstage Mortality in Patients With No History of Arrhythmia After Stage I Palliation for Single Ventricle Heart Disease

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2016
Background Interstage mortality (IM) remains significant after stage 1 palliation (S1P) for single‐ventricle heart disease (SVD), with many deaths sudden and unexpected.
David W Brown, Colleen Mangeot, Jeffrey B. Anderson, L. E. Peterson, E. King, Stacey L. Lihn, S. Neish, C. Fleishman, Christina M. Phelps, Samuel P. Hanke, R. Beekman, C. Lannon   +11 more
semanticscholar   +1 more source